Harvard Bioscience (HBIO) Accumulated Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has reported Accumulated Expenses for 17 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 15.75% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 15.75% YoY), while the FY2025 annual figure was $1.8 million, up 5.89% from the prior year.
• Accumulated Expenses rose to $2.2 million in Q1 2026 per HBIO's latest filing, from $1.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $4.8 million in Q1 2022 and bottomed at $1.7 million in Q4 2024.
• Historically, Accumulated Expenses has averaged $2.8 million across 5 years, with a median of $3.1 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 77.57% — and 2024, when it plunged 56.38%.
• Harvard Bioscience's Accumulated Expenses stood at $3.5 million in 2022, then rose by 13.03% to $3.9 million in 2023, then slumped by 56.38% to $1.7 million in 2024, then advanced by 5.89% to $1.8 million in 2025, then grew by 19.83% to $2.2 million in 2026.
• Business Quant data shows HBIO's Accumulated Expenses at $2.2 million in Q1 2026, $1.8 million in Q4 2025, and $1.9 million in Q3 2025.